Why do some melanoma patients respond to immunotherapy? new study investigates
NCT ID NCT02626065
First seen Nov 01, 2025 · Last updated May 16, 2026 · Updated 23 times
Summary
This study looked at 32 people with advanced melanoma who were treated with the immunotherapy drug Nivolumab (Anti-PD1). The goal was to understand how the immune system changes during treatment and why some patients respond well while others do not. By analyzing blood samples before and during treatment, researchers hope to find clues that could lead to better treatment strategies.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC MELANOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Centre Hospitalier Lyon Sud
Pierre-Bénite, 69310, France
Conditions
Explore the condition pages connected to this study.